HHS Announces 340B Drug Rebate Pilot Program

September 9, 2025

EGWP Medicare

On Aug. 1, the Office of Pharmacy Affairs (OPA), which oversees the 340B program within the Health Resources and Services Administration (HRSA) at HHS, announced a new voluntary pilot program to test post-purchase rebates for drugs subject to Medicare’s Maximum Fair Price (MFP).

Set to launch in 2026, the pilot allows 340B covered entities to buy the 10 drugs subject to Medicare negotiated prices at commercial prices and receive post-sale rebates from manufacturers rather than receiving upfront discounts.

The pilot is designed to improve transparency; help address inappropriately duplicated discounts; and to evaluate the feasibility, fairness, and transparency of rebate models. It includes strict requirements for data collection, reporting, and rebate processing, and prohibits rebate denials for diversion or duplicate discounts.

Initiatives

Calls grow for Drug Patent reform

In a recent blog post, the Pharmaceutical Care Management Association (PCMA) highlighted increased attention to pharmaceutical companies’ abuse of drug patents. Last month, the Supreme Court unanimously ruled in favor of a generic drugmaker in a “skinny labeling” case, a victory for patients. Skinny labels allow generic and biosimilar competitors to launch products for non-patented indications, helping accelerate […]
read more >

August 11, 2026

EGWP marketplace medicaid Medicare

perspectives

AHIP calls for Bipartisan reform to address health care cost drivers

On July 23, AHIP President and CEO Mike Tuffin wrote an opinion piece in The New York Times saying, “common-sense bipartisan reforms are needed to promote competition in care delivery and prescription drugs, protect consumers from providers and drugmakers’ anticompetitive practices and transition away from the perverse incentives of fee-for-service medicine.” Tuffin notes that health […]
read more >

August 11, 2026

EGWP marketplace medicaid Medicare

Solutions

PCMA urges preserving patient access and flexibility in new fertility benefits rule

PCMA recently submitted comments to HHS, DOL, and the Treasury (the Departments) in response to the proposed rule establishing a new category of limited excepted benefits for fertility services. PCMA supports the Departments’ goal of expanding access to fertility care while encouraging employer innovation but urged several targeted refinements to ensure the framework is operationally […]
read more >

August 11, 2026

marketplace medicaid

You may also like